Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical combination of nifedipine (0.3%) and lidocaine (1.5%) developed by the University of Calgary for the treatment of chronic anal fissure. Nifedipine, a calcium channel blocker, works by reducing internal anal sphincter hypertonia, thereby improving local blood flow and facilitating the healing of the fissure. Lidocaine acts as a local anesthetic to provide immediate pain relief by blocking sodium channels in nerve fibers. This combination is being studied in a Phase 2/3 clinical trial as a non-invasive alternative to surgical interventions like lateral internal sphincterotomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nifedipine + lidocaine.